Article Information
History
- November 16, 2020.
Article Versions
- You are currently viewing Version 1 of this article (November 16, 2020 - 10:18).
- Version 2 (January 7, 2021 - 11:06).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Cara E. Brook1,*,
- Graham R. Northrup2,
- Alexander J. Ehrenberg1,3,4,5,
- the IGI Testing Consortium3,
- Jennifer A. Doudna3,6,7,8,9 and
- Mike Boots1,10
- 1Department of Integrative Biology, University of California, Berkeley
- 2Center for Computational Biology, College of Engineering, University of California, Berkeley
- 3Innovative Genomics Institute, University of California, Berkeley
- 4Helen Wills Neuroscience Institute, University of California, Berkeley
- 5Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco
- 6Department of Molecular and Cell Biology, University of California, Berkeley
- 7College of Chemistry, University of California, Berkeley
- 8J. David Gladstone Institutes, San Francisco, CA
- 9Howard Hughes Medical Institute, University of California, Berkeley
- 10Department of Biosciences, University of Exeter, Penryn, UK
- ↵*corresponding author: Cara E. Brook, address: 5017 Valley Life Sciences Building, University of California, Berkeley, phone: 707-241-5550, email: cbrook{at}berkeley.edu
Posted November 16, 2020.
Optimizing COVID-19 control with asymptomatic surveillance testing in a university environment
